Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in: Wiener Medizinische Wochenschrift 13-14/2019

06.03.2018 | main topic

The value of metastasectomy in stage IV cutaneous melanoma

verfasst von: Prof. Dr. Uwe Wollina, MD, Piotr Brzezinski

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2019

Einloggen, um Zugang zu erhalten

Summary

Cutaneous melanoma is an aggressive neoplasia of melanocytes. Prognosis is dependent on tumor stage. Stage IV melanoma is characterized by the occurrence of distant metastases. Response of metastases to classical chemotherapy is limited and toxicity of treatment is high. In recent years, new developments in immunotherapy and targeted therapies improved prognosis of stage IV melanoma patients with better tolerability of treatment. There is no dispute about surgical treatment of primary melanoma. But what is the value of metastasectomy in the era of new systemic treatments? This review aims to discuss available data for surgical removal of distant metastases for several organs and tissues. The available evidence suggests that for selected patients with possible complete resection of all tumor metastases, metastasectomy remains an effective treatment option with a benefit in overall survival.
Vorheriger Artikel Clinical melanoma characteristics and survival—a single-center retrospective study between 2000 and 2010
Nächster Artikel Evidenzbasierte Empfehlungen zur Überarbeitung der österreichischen Vorsorgeuntersuchung
Literatur
1.
Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma. Mod Pathol. 2006;19(Suppl 2):S41–S70.CrossRefPubMed
2.
Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–40.PubMed
3.
Berwick M, Buller DB, Cust A, et al. Melanoma epidemiology and prevention. Cancer Treat Res. 2016;167:17–49.CrossRefPubMed
4.
5.
Lugowska I, Szkultecka-Dębek M, Sozańska-Solak A, et al. Stage III/IV melanoma in Poland: epidemiology, standard of care and treatment related costs. J Health Policy Outcomes Res. 2012;2(2):41–7.
6.
Testori A, Ribero S, Bataille V. Diagnosis and treatment of in-transit melanoma metastases. Eur J Surg Oncol. 2017;43(3):544–60.CrossRefPubMed
7.
Leiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol. 2010;17(1):129–37.CrossRefPubMed
8.
Beger J, Hansel G, Krönert C, et al. A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. Int J Dermatol. 2013;52(2):220–30.CrossRefPubMed
9.
Satzger I, Meier A, Hoy L, et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol. 2011;18(2):514–20.CrossRefPubMed
10.
Geimer T, Sattler EC, Flaig MJ, et al. The impact of sentinel node dissection on disease-free and overall tumour-specific survival in melanoma patients: a single centre group-matched analysis of 1192 patients. J Eur Acad Dermatol Venereol. 2017;31(4):629–35.CrossRefPubMed
11.
Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2.CrossRefPubMedPubMedCentral
12.
Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67.CrossRefPubMed
13.
Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.CrossRefPubMedPubMedCentral
14.
Bartlett EK, Simmons KD, Wachtel H, et al. The rise in metastasectomy across cancer types over the past decade. Cancer. 2015;121(5):747–57.CrossRefPubMed
15.
Tronnier M, Semkova K, Wollina U, Tchernev G. Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach. Wien Med Wochenschr. 2013;163(15–16):354–8.CrossRefPubMed
16.
17.
Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–55.CrossRefPubMedPubMedCentral
18.
Forschner A, Eichner F, Amaral T, Keim U, Garbe C, Eigentler TK. Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). J Cancer Res Clin Oncol. 2017;143(3):533–40.CrossRefPubMed
19.
Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104(2):111–5.CrossRefPubMedPubMedCentral
20.
Deutsch GB, Flaherty DC, Kirchoff DD, et al. Association of surgical treatment, systemic therapy, and survival in patients with abdominal visceral melanoma metastases, 1965–2014: Relevance of surgical cure in the era of modern systemic therapy. Jama Surg. 2017;152(7):672–8.CrossRefPubMedPubMedCentral
21.
Collinson FJ, Lam TK, Bruijn WM, et al. Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy. Ann Surg Oncol. 2008;15(6):1741–9.CrossRefPubMed
22.
Flaherty DC, Deutsch GB, Kirchoff DD, et al. Adrenalectomy for metastatic melanoma: current role in the age of nonsurgical treatments. Am Surg. 2015;81(10):1005–9.PubMedPubMedCentral
23.
Ryu SW, Saw R, Scolyer RA, Crawford M, Thompson JF, Sandroussi C. Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries. J Surg Oncol. 2013;108(2):129–35.CrossRefPubMed
24.
Zekri J, Marples M, Taylor D, Kandukurti K, McParland L, Brown JE. Complications of bone metastases from malignant melanoma. J Bone Oncol. 2017;8:13–7.CrossRefPubMedPubMedCentral
25.
Colman MW, Kirkwood JM, Schott T, Goodman MA, McGough RL 3rd. Does metastasectomy improve survival in skeletal melanoma? Melanoma Res. 2014;24(4):354–9.CrossRefPubMed
26.
Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117(8):1697–703.CrossRefPubMed
27.
Pessina F, Navarria P, Cozzi L, et al. Role of surgical resection in patients with single large brain metastases: feasibility, morbidity, and local control evaluation. World Neurosurg. 2016;94:6–12.CrossRefPubMed
28.
29.
Brown RE, Ross MI, Edwards MJ, et al. The prognostic significance of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2010;17(12):3330–5.CrossRefPubMed
30.
Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(4):450–73.CrossRefPubMed
31.
Delgado AF, Delgado AF. Complete lymph node dissection in melanoma: a systematic review and meta-analysis. Anticancer Res. 2017;37(12):6825–9.PubMed
32.
Treasure T, Milošević M, Fiorentino F, Macbeth F. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax. 2014;69(10):946–9.CrossRefPubMed
33.
Schuhan C, Muley T, Dienemann H, Pfannschmidt J. Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac Cardiovasc Surg. 2011;59(3):158–62.CrossRefPubMed
34.
Younes R, Abrao FC, Gross J. Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival. Melanoma Res. 2013;23(4):307–11.PubMed
35.
Chua TC, Scolyer RA, Kennedy CW, Yan TD, McCaughan BC, Thompson JF. Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol. 2012;19(6):1774–81.CrossRefPubMed
36.
Guerrini GP, Lo Faso F, Vagliasindi A, et al. The role of minimally invasive surgery in the treatment of lung metastases. J Invest Surg. 2017;30(2):110–5.CrossRefPubMed
37.
Lo Faso F, Solaini L, Lembo R, et al. Thoracoscopic lung metastasectomies: a 10-year, single-center experience. Surg Endosc. 2013;27(6):1938–44.CrossRefPubMedPubMedCentral
38.
Abdelnour-Berchtold E, Perentes JY, Ris HB, et al. Survival and local recurrence after video-assisted thoracoscopic lung metastasectomy. World J Surg. 2016;40(2):373–9.CrossRefPubMed
39.
Eckardt J, Licht PB. Thoracoscopic versus open pulmonary metastasectomy: a prospective, sequentially controlled study. Chest. 2012;142(6):1598–602.CrossRefPubMed
40.
Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007;14(10):2847–53.CrossRefPubMed
41.
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca Cancer J Clin. 2017;67(6):472–92.CrossRefPubMedPubMedCentral
42.
Garbe C, Peris K, Hauschild A, et al. European consensus-based interdisciplinary guideline—update. Eur J Cancer. 2016;2016(63):201–17.CrossRef
43.
44.
Austin E, Mamalis A, Ho D, Jagdeo J. Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review. Arch Dermatol Res. 2017;309(4):229–42.CrossRefPubMed
45.
Amaral T, Tampouri I, Garbe C. How to use neoadjuvant medical treatment to maximize surgery in melanoma. Expert Rev Anticancer Ther. 2018;18(2):121–30.CrossRefPubMed
46.
Hao C, Tian J, Liu H, Li F, Niu H, Zhu B. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(26):e7325.CrossRef
47.
Baker JJ, Stitzenberg KB, Collichio FA, Meyers MO, Ollila DW. Systematic review: surgery for patients with metastatic melanoma during active treatment with ipilimumab. Am Surg. 2014;80(8):805–10.PubMed
48.
Faries MB, Mozzillo N, Kashani-Sabet M, et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24(13):3991–4000.CrossRefPubMed
49.
Klemen ND, Feingold PL, Goff SL, et al. Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. Ann Surg Oncol. 2017;24(1):135–41.CrossRefPubMed
50.
Najem A, Krayem M, Perdrix A, et al. New drug combination strategies in melanoma: current status and future directions. Anticancer Res. 2017;37(11):5941–53.PubMed
51.
He M, Lovell J, Ng BL, et al. Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication. J Surg Oncol. 2015;111(8):980–4.CrossRefPubMed
52.
Zippel D, Markel G, Shapira-Frommer R, et al. Perioperative BRAF inhibitors in locally advanced stage III melanoma. J Surg Oncol. 2017;116(7):856–61.CrossRefPubMed
53.
54.
Raigani S, Cohen S, Boland GM. The role of surgery for melanoma in an era of effective systemic therapy. Curr Oncol Rep. 2017;19(3):17.CrossRefPubMed
55.
Wollina U. Late recurrence is a sign of melanoma dormancy: need of life-long follow-up of melanoma patients. In: Hayat MA, editor. Tumor dormancy, quescience, and senescence. Aging, cancer, and noncancer pathologies. Vol. 1. Dordrecht: Springer; 2013. pp. 79–83.CrossRef
Metadaten
Titel
The value of metastasectomy in stage IV cutaneous melanoma
verfasst von
Prof. Dr. Uwe Wollina, MD
Piotr Brzezinski
Publikationsdatum
06.03.2018
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 13-14/2019
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-018-0630-6

Weitere Artikel der Ausgabe 13-14/2019

Wiener Medizinische Wochenschrift 13-14/2019 Zur Ausgabe

editorial

Melanom

editorial

wmw history

main topic

Clinical melanoma characteristics and survival—a single-center retrospective study between 2000 and 2010

originalarbeit

Evidenzbasierte Empfehlungen zur Überarbeitung der österreichischen Vorsorgeuntersuchung

main topic

Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies

case report

A rare case of cancer-to-cancer metastasis: breast cancer to renal cell cancer